Hysteroscopic tubal cannulation and flushing Medical Services in China

Hysteroscopic tubal cannulation and flushing is a minimally invasive, outpatient surgical procedure performed within the reproductive medicine specialty to diagnose and treat proximal tubal occlusion—a common cause of female infertility. It involves the insertion of a hysteroscope through the cervix into the uterine cavity, followed by precise catheter-guided cannulation of the fallopian tube ostia (cornual openings) under direct visualization. A saline or contrast medium is then gently flushed to assess tubal patency and potentially dislodge mucus plugs, fibrin debris, or mild adhesions obstructing the intramural or isthmic segments. Unlike laparoscopic surgery or IVF, this technique targets mechanical blockages at the uterotubal junction without requiring abdominal incisions or general anesthesia in most cases. Pathophysiologically, proximal tubal occlusion often arises from chronic endometritis, post-infectious scarring (e.g., following chlamydia or gonorrhea), iatrogenic trauma (e.g., after abortion or curettage), or silent intrauterine inflammation leading to cornual stenosis or functional spasm. Epidemiologically, proximal tubal obstruction accounts for approximately 10–25% of all tubal factor infertility cases, with prevalence estimates ranging from 8% to 15% among women undergoing fertility evaluation in tertiary reproductive centers across China and other high-income countries. Risk factors include prior pelvic inflammatory disease (PID), history of uterine instrumentation (e.g., D&C, IUD insertion/removal), recurrent miscarriage, endometrial tuberculosis (especially in endemic regions), and chronic endometrial immune dysregulation. Importantly, many affected women are asymptomatic—lacking classic signs like pelvic pain or fever—making diagnosis reliant on hysterosalpingography (HSG) or sonohysterography as screening tools. The quality-of-life impact is profound yet often underrecognized: patients frequently experience emotional distress, marital strain, social stigma, diminished self-worth, and financial burden due to prolonged infertility journeys. While not curative for severe tubal damage or distal obstruction, successful cannulation restores natural conception potential in 25–45% of appropriately selected patients within 6–12 months post-procedure—offering a cost-effective, fertility-preserving alternative before advancing to assisted reproductive technologies. Patient selection is critical: ideal candidates demonstrate unilateral or bilateral proximal occlusion on HSG with normal distal anatomy, no hydrosalpinx, and preserved ovarian reserve. Complications are rare (<2%) and include transient cramping, uterine perforation (0.1–0.3%), or tubal spasm mimicking obstruction; however, real-time hysteroscopic guidance significantly improves diagnostic accuracy over HSG alone and reduces false-positive occlusion rates by up to 30%.

Hysteroscopic tubal cannulation and flushing is a minimally invasive, diagnostic and therapeutic procedure performed in reproductive medicine to evaluate and potentially restore patency of the proximal fallopian tubes—specifically the intramural and isthmic segments. It is indicated primarily in cases of suspected proximal tubal occlusion (PTO), a common cause of infertility affecting approximately 10–25% of infertile women. The most frequent underlying causes of PTO include post-infectious tubal scarring, particularly following subclinical or inadequately treated endometritis, chlamydial infection, or other ascending genital tract infections. Chronic endometritis—often associated with persistent low-grade inflammation due to bacterial biofilms (e.g., *Chlamydia trachomatis*, *Mycoplasma hominis*, or mixed anaerobic flora)—can lead to endosalpingeal edema, mucosal adhesions, and functional tubal blockage without gross anatomical distortion. Other common etiologies include iatrogenic injury from prior uterine instrumentation (e.g., dilation and curettage, intrauterine device insertion/removal, or hysteroscopic resection), postpartum or postabortal endometritis, and silent granulomatous inflammation (e.g., from tuberculosis in endemic regions). Endometrial polyps or submucosal fibroids near the tubal ostia may mechanically obstruct tubal entry, while congenital anomalies such as tubal hypoplasia or ostial stenosis—though rare—may also contribute to apparent occlusion.

Triggers for procedural candidacy typically involve unexplained infertility after standard evaluation (including normal semen analysis, ovulation confirmation, and documentation of at least one patent tube via hysterosalpingography [HSG] or sonohysterography), coupled with HSG findings suggestive of unilateral or bilateral proximal filling defects. A 'string-of-pearls' appearance on HSG, delayed contrast passage, or failure of contrast to enter the tube despite adequate uterine pressure often prompts consideration of hysteroscopic intervention. Acute pelvic inflammatory disease or active genital tract infection constitutes an absolute contraindication and must be ruled out clinically and microbiologically prior to the procedure.

Key risk factors for both PTO development and procedural complications include prior pelvic surgery (especially multiple D&Cs or myomectomies), history of sexually transmitted infections (particularly untreated or recurrent chlamydia), use of intrauterine devices (IUDs) in high-risk populations, and socioeconomic factors limiting access to timely STI screening and treatment. Obesity (BMI ≥30 kg/m²) is associated with increased intraoperative technical difficulty, reduced visualization, and higher rates of incomplete cannulation due to uterine distension challenges and altered pelvic anatomy. Advanced maternal age (>35 years) correlates with diminished endometrial receptivity and reduced likelihood of spontaneous conception post-procedure, though it does not directly increase mechanical occlusion risk.

Genetic factors play a limited but emerging role. Polymorphisms in immune response genes—including *TLR4* (Toll-like receptor 4), *TNF-α* promoter variants, and *IL-10* haplotypes—have been associated with exaggerated or dysregulated inflammatory responses to genital pathogens, predisposing carriers to more severe tubal damage following infection. Additionally, mutations in genes involved in epithelial repair (e.g., *MUC1*, *FOXO1*) may impair mucosal restitution after injury, promoting fibrosis and luminal obliteration. However, no monogenic disorder is definitively linked to isolated PTO; rather, susceptibility appears polygenic and context-dependent.

Environmental factors significantly modulate risk. Exposure to environmental endocrine-disrupting chemicals (EDCs)—such as bisphenol A (BPA), phthalates, and dioxins—has been correlated with altered tubal ciliary function, disrupted oviductal smooth muscle contractility, and aberrant expression of adhesion molecules (e.g., integrins, selectins), potentially contributing to functional tubal impairment even in the absence of structural occlusion. Smoking is a well-established modifiable risk factor: nicotine and carbon monoxide induce vasoconstriction, reduce tubal blood flow, impair ciliary beat frequency, and promote oxidative stress in tubal epithelium—increasing susceptibility to infection-related damage and decreasing post-procedural fertility outcomes. Occupational exposure to organic solvents (e.g., in textile or printing industries) and chronic psychosocial stress—via hypothalamic-pituitary-adrenal axis dysregulation and elevated proinflammatory cytokines—may further compromise tubal microenvironment homeostasis. Importantly, hysteroscopic tubal cannulation itself carries procedural risks including uterine perforation (<1%), intravasation of distension medium, false passage creation, tubal spasm mimicking occlusion, and rare infection transmission. Success rates vary widely (30–70%) depending on operator expertise, equipment quality (e.g., 3Fr microcatheters vs. rigid cannulas), and underlying pathology—highlighting the importance of careful patient selection and integration with broader fertility management strategies.

Hysteroscopic tubal cannulation and flushing is a minimally invasive, diagnostic and therapeutic procedure performed in reproductive medicine to evaluate and potentially restore patency of the proximal fallopian tubes—specifically addressing proximal tubal occlusion (PTO), which accounts for approximately 10–25% of female factor infertility cases. As an interventional hysteroscopic technique, it is not a disease entity itself; therefore, it does not produce intrinsic symptoms. Rather, patients undergoing this procedure typically present with clinical manifestations attributable to underlying tubal pathology or associated reproductive dysfunction. Understanding the symptomatology requires careful contextualization of pre-procedural clinical presentation, intraoperative observations, and post-procedural sequelae—including expected physiological responses, adverse events, and potential complications.

Early symptoms refer to subtle, often nonspecific indicators prompting initial fertility evaluation. These include primary or secondary infertility (failure to conceive after ≥12 months of regular, unprotected intercourse), unexplained infertility despite normal ovulation, patent distal tubes on hysterosalpingography (HSG), and recurrent early pregnancy loss possibly linked to chronic endometritis or tubal microenvironment abnormalities. Some patients report mild, cyclic lower abdominal discomfort or intermittent pelvic pressure—though these are rarely isolated or pathognomonic. Importantly, proximal tubal occlusion is frequently asymptomatic; many individuals remain unaware of tubal compromise until infertility workup reveals unilateral or bilateral PTO on imaging.

Typical symptoms are those directly associated with the procedural experience and immediate post-procedural period. During hysteroscopic cannulation, patients under conscious sedation or general anesthesia do not perceive pain; however, under local anesthesia, transient crampy uterine contractions—similar to moderate menstrual colic—are commonly reported as the hysteroscope advances into the endocervical canal and uterine cavity, and especially during selective catheterization of the tubal ostia. Successful cannulation is often accompanied by subjective relief of pressure upon saline or contrast medium passage through the tube, sometimes perceived as a ‘release’ sensation. Post-procedurally, within 24–48 hours, patients typically experience mild to moderate suprapubic or lower abdominal cramping (resembling dysmenorrhea), light vaginal spotting or serosanguineous discharge lasting ≤3 days, and transient fatigue. These are considered expected physiological responses to mechanical instrumentation, endometrial manipulation, and hydrodistension of the uterine cavity.

Accompanying symptoms reflect comorbid gynecologic or systemic conditions frequently coexisting with PTO. Chronic endometritis—often subclinical but prevalent in infertile populations—may manifest as intermenstrual spotting, prolonged menses, or postcoital bleeding. Endometriosis-associated symptoms include deep dyspareunia, cyclical bowel or bladder discomfort, and chronic pelvic pain exacerbated premenstrually. Patients with prior pelvic inflammatory disease (PID) may report historical episodes of acute pelvic pain, fever, or purulent vaginal discharge. Additionally, hormonal imbalances such as luteal phase defect or hyperprolactinemia may coexist, presenting with oligomenorrhea, anovulatory cycles, or galactorrhea—though these are not causally linked to tubal occlusion per se.

Complications, while uncommon (<5% overall incidence), constitute critical symptom domains requiring prompt recognition. Acute intraoperative complications include uterine perforation—manifested by sudden sharp lower abdominal pain, hemodynamic instability, or visualization of abdominal viscera through the hysteroscope—requiring immediate cessation and surgical consultation. Cervical laceration may cause brisk vaginal bleeding and localized tenderness. Post-procedural infectious complications (endometritis, salpingitis, or pelvic abscess) present with fever (>38.0°C), worsening pelvic pain, purulent vaginal discharge, and systemic signs such as tachycardia or leukocytosis—typically emerging 48–96 hours post-procedure. Rarely, intravasation of distention media (e.g., glycine or saline) may lead to fluid overload, hyponatremia, or pulmonary edema, evidenced by dyspnea, confusion, or hypertension. Tubal spasm or false passage creation during cannulation may result in failed recanalization without overt symptoms but clinically apparent as persistent infertility or subsequent HSG showing unchanged occlusion.

Diagnosis of indications for hysteroscopic tubal cannulation relies on multimodal assessment. HSG remains the first-line imaging modality: it identifies 'horn-shaped' filling defects at the cornual region, non-filling of the proximal tube despite adequate uterine opacification, or abrupt cutoff at the uterotubal junction—highly suggestive of PTO. However, HSG cannot differentiate true obstruction from functional spasm or mucosal debris. Transvaginal hydrosalpinx sonography with saline infusion sonohysterography (SIS) offers dynamic real-time assessment of tubal patency and endometrial morphology. Diagnostic hysteroscopy—performed immediately prior to cannulation—confirms absence of intrauterine pathology (polyps, synechiae, submucosal fibroids) that could impede cannulation or confound interpretation. Intraoperative fluoroscopic or ultrasound-guided contrast injection during hysteroscopy provides definitive confirmation of successful tubal traversal and distal spill. Serum markers such as CA-125 may be elevated in chronic salpingitis but lack specificity; endometrial biopsy with immunohistochemistry for CD138+ plasma cells is indicated if chronic endometritis is suspected.

Differential diagnosis centers on distinguishing true proximal tubal occlusion from mimicking conditions. Functional tubal spasm—induced by anxiety, cold irrigation fluid, or excessive cervical traction—may transiently mimic occlusion on HSG but resolves spontaneously or with antispasmodics (e.g., hyoscine butylbromide). Cornual block due to müllerian anomalies (e.g., unicornuate uterus with rudimentary horn) presents with asymmetric uterine cavities on 3D ultrasound or MRI and absent contralateral tubal ostium on hysteroscopy. Endometrial polyps or intracavitary adhesions near the tubal ostia may mechanically obstruct catheter passage but are visually identifiable and treatable during hysteroscopy. Distal tubal disease (e.g., hydrosalpinx, peritubal adhesions) must be excluded via laparoscopy or MRI, as hysteroscopic cannulation is ineffective for distal pathology. Finally, congenital tubal agenesis or segmental atresia—confirmed by absence of tubal tissue on MRI or laparoscopy—requires genetic counseling rather than intervention. Accurate differentiation prevents unnecessary procedures and guides appropriate management: expectant observation for spasm, surgical correction for anatomical variants, or IVF for irreversible tubal damage.

Hysteroscopic tubal cannulation and flushing is a minimally invasive, diagnostic and therapeutic procedure performed within the field of reproductive medicine to evaluate and manage proximal tubal occlusion—a common cause of female factor infertility. This intervention targets blockages located at the uterotubal junction (UTJ), where the fallopian tube meets the uterine cavity, often resulting from mucus plugs, functional spasm, or mild synechiae rather than severe structural damage. The procedure is conducted under direct hysteroscopic visualization using a 2–3 mm rigid or flexible hysteroscope, with simultaneous fluoroscopic or ultrasound guidance in many centers to confirm tubal patency and contrast flow.

Conservative treatment remains the first-line approach for patients with suspected proximal tubal obstruction, particularly when clinical suspicion is low or symptoms are nonspecific. This includes expectant management with timed intercourse during the fertile window, lifestyle optimization (e.g., smoking cessation, BMI normalization, stress reduction), and ovulation monitoring via basal body temperature charting or urinary luteinizing hormone (LH) assays. In select cases—especially those with documented chronic endometritis or subclinical pelvic inflammation—empirical antibiotic therapy may be considered. A 14-day course of doxycycline (100 mg twice daily) combined with metronidazole (500 mg twice daily) has demonstrated efficacy in resolving inflammatory tubal spasm and improving subsequent patency rates in observational studies. However, conservative measures alone lack objective verification of tubal status and are not recommended when infertility persists beyond 12 months (or 6 months in women ≥35 years) without evidence of other contributing factors.

Pharmacologic interventions are adjunctive rather than definitive. While no FDA- or EMA-approved medications exist specifically for tubal recanalization, gonadotropin-releasing hormone (GnRH) antagonists such as cetrorelix (0.25 mg subcutaneously) administered immediately prior to hysteroscopy have been used off-label to reduce uterine contractility and minimize procedural discomfort and false-positive occlusion diagnoses due to functional spasm. Similarly, intracervical or intrauterine local anesthesia (e.g., 2% lidocaine gel) and systemic NSAIDs (e.g., ibuprofen 600 mg one hour pre-procedure) improve patient tolerance. Post-procedural anti-inflammatory regimens—including short-term oral NSAIDs for 48–72 hours—are routinely prescribed to mitigate peritubal edema and prevent re-occlusion. Hormonal priming with estrogen (e.g., estradiol valerate 2 mg daily for 5 days prior) may enhance endometrial receptivity and reduce intrauterine adhesion formation in susceptible individuals, though robust randomized data supporting this practice remain limited.

Surgical treatment centers on hysteroscopic tubal cannulation and flushing, typically performed in an outpatient setting under conscious sedation or paracervical block. After cervical preparation and uterine distension with saline or carbon dioxide, the hysteroscope is advanced into the uterine cavity. Under direct vision, a coaxial microcatheter system (e.g., Cook FALP or SIS-Flushing Catheter) is navigated through the ostium into the proximal 1–2 cm of the fallopian tube. Gradual hydrostatic pressure (typically 100–150 mmHg) is applied using warmed saline or diluted contrast medium (e.g., 20% water-soluble iodinated contrast). Successful cannulation is confirmed by visible catheter advancement, absence of backflow, and distal spillage observed fluoroscopically or via sonographic contrast (HyCoSy). The procedure is bilateral and repeated for each tube. In cases of resistant occlusion, mechanical dilation with calibrated guidewires (≤0.014 inch) may be employed cautiously; however, aggressive instrumentation carries risks of tubal perforation or false passage. Contraindications include active pelvic infection, uncontrolled coagulopathy, severe intrauterine pathology (e.g., large submucosal fibroids or extensive synechiae), and pregnancy. Complication rates are low (<2%), with most adverse events being transient—such as mild cramping, spotting, or vasovagal response. Rare but serious complications include uterine perforation, intravasation of fluid/contrast, and pelvic infection.

China offers distinct advantages in the delivery of hysteroscopic tubal cannulation and flushing. First, the national integration of reproductive medicine with high-volume tertiary hospitals enables standardized protocols, rapid access to advanced imaging (including real-time 3D-HyCoSy and digital subtraction hysterosalpingography), and multidisciplinary coordination with embryology and endocrinology units. Second, China’s widespread adoption of disposable hysteroscopic equipment—particularly single-use rigid hysteroscopes and integrated irrigation-cannulation systems—significantly reduces cross-contamination risk and eliminates sterilization-related delays, enhancing procedural safety and throughput. Third, cost-effectiveness is notable: the average out-of-pocket expense for the procedure in public Class III-A hospitals ranges from USD 350–600, substantially lower than equivalent care in North America or Western Europe, while maintaining adherence to ISO 13485–certified device standards. Fourth, Chinese reproductive centers increasingly incorporate AI-assisted image analysis for real-time assessment of tubal dynamics and predictive modeling of post-procedure natural conception likelihood—enhancing personalized counseling. Finally, national clinical guidelines (e.g., the 2023 Chinese Medical Association Reproductive Medicine Branch Consensus) strongly endorse this procedure as a first-tier intervention before proceeding to IVF, reflecting robust local evidence demonstrating 35–45% 12-month cumulative natural pregnancy rates following successful cannulation in carefully selected patients with isolated proximal occlusion.

Recovery advice emphasizes early mobilization and symptom monitoring. Patients are advised to resume normal non-strenuous activities within 24 hours but avoid sexual intercourse, tampon use, swimming, and heavy lifting (>5 kg) for 7–10 days to minimize infection and bleeding risk. Mild cramping and serosanguineous vaginal discharge for up to 48 hours are expected; persistent fever (>38.0°C), foul-smelling discharge, or severe pelvic pain warrant immediate evaluation for infection. A follow-up transvaginal ultrasound at day 7–10 assesses for hydrosalpinx development or residual fluid collections. Ovulation induction with clomiphene citrate or letrozole may be initiated in the subsequent cycle if spontaneous conception does not occur, and timed intercourse is encouraged. Serial serum progesterone testing or mid-luteal phase endometrial biopsy may be considered in recurrent implantation failure after cannulation to rule out luteal phase defect. Importantly, patients should understand that successful cannulation does not guarantee fertility restoration—especially in cases with concomitant distal tubal disease, diminished ovarian reserve, or male factor infertility—and timely escalation to assisted reproductive technologies (ART) is recommended if conception fails within six months post-procedure. Comprehensive pre-procedural counseling, including realistic expectations, psychological support, and shared decision-making, forms the cornerstone of ethical and effective reproductive care.